Skip to main content

Cherington Charles's Form 4 filing

Comera Life Sciences Holdings, Inc. (CMRA) · filed Oct 24, 2022

Accession no.
0001062993-22-021051
Filed
Oct 24, 2022
Trade date
Oct 20-21, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $23.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cherington CharlesCIK 000144869810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 20, 2022Common StockPPurchaseAcquired+3,316$1.52F1+$5,040.32638,246Direct
Oct 21, 2022Common StockPPurchaseAcquired+11,691$1.59F2+$18,588.69649,937Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.54 inclusive. The report person undertakes to provide to Comera Life Sciences Holdings, Inc. ("Comera"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.46 to $1.65 inclusive. The report person undertakes to provide to Comera Life Sciences Holdings, Inc. ("Comera"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 2.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)